☆ 4.3 Article

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Gastroenterological safety of IL-17 inhibitors: a systematic literature review

Benedicte Caron et al.

Summary: IL-17 inhibitors are considered safe and effective in treating psoriasis, psoriatic arthritis, and ankylosing spondylitis. The incidence of new-onset inflammatory bowel disease or exacerbation of preexisting inflammatory bowel disease with anti-IL-17 agents is low. Clinicians should be cautious of these potential risks when prescribing this therapy.

EXPERT OPINION ON DRUG SAFETY (2022)

Add to Collection

Article Dermatology

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

Paolo Dapavo et al.

Summary: This study compared the efficacy, safety, and drug survival of anti TNF-alpha, anti-IL-17, and anti-IL-23 in psoriasis treatment. Ixekizumab showed superior efficacy in terms of PASI90 and PASI100, but did not have higher drug survival as expected. Secukinumab was the only drug with higher drug survival among bio-naive patients.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Article Rheumatology

Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System

Laetitia Penso et al.

Summary: This study investigated whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) increased the risk of inflammatory bowel disease (IBD) in patients with psoriasis (PsO) and psoriatic arthritis (PsA)/ankylosing spondylitis (AS). The results showed that patients initiating IL-17i treatment did not have a higher risk of developing IBD compared to patients receiving other treatments.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Health Care Sciences & Services

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Linda Davidson et al.

Summary: There is a significant increase in the risk of candidiasis during Th17 inhibitor therapy, particularly for oropharyngeal, esophageal, and cutaneous candidiasis.

LANCET REGIONAL HEALTH-EUROPE (2022)

Add to Collection

Article Dermatology

Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry

Benjamin Lockshin et al.

Summary: In a study of real-world patients with psoriasis, initiators of ixekizumab had longer drug survival compared to initiators of TNF inhibitors and other IL-17 inhibitors, with persistence up to 2 years of follow-up.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Dermatology

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic

Martina Kojanova et al.

Summary: The study identified significant differences between men and women with psoriasis in terms of age, disease duration, comorbidities, disease severity, quality of life, and treatment outcomes. Women were older at the onset of biological treatment, had longer disease durations, were more likely to have psoriatic arthritis, and experienced lower drug survival rates compared to men.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Dermatology

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Martina Kojanova et al.

Summary: The study aimed to evaluate the real-world effectiveness of adalimumab and investigate factors affecting treatment persistence. More than 1150 psoriasis patients in the Czech Republic were included in the analysis, with treatment effectiveness defined by PASI improvement. Factors such as baseline PASI score, previous biological therapies, and gender were associated with shorter adalimumab survival. This long-term study demonstrated that adalimumab is effective with high treatment persistence.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Rheumatology

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis-A Retrospective Database Study

Philipp Sewerin et al.

Summary: This study investigated drug survival for bDMARDs in German PsA patients, finding an overall persistence rate of 57.5% with variations depending on the specific bDMARD used. Male patients had a significantly lower risk of treatment discontinuation.

RHEUMATOLOGY AND THERAPY (2021)

Add to Collection

Article Dermatology

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres et al.

Summary: In this study, drug survival analysis of the most recent biologic agents approved for the treatment of psoriasis was conducted. Factors such as female sex, higher BMI, and prior exposure to biologic agents were found to significantly increase the risk of drug discontinuation. The study also showed that the drug survival of guselkumab and risankizumab was higher than that of ustekinumab, while secukinumab had a lower drug survival rate.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis

Chongru He et al.

Summary: This study assessed the efficacy and safety of interleukin-17 inhibitors in patients with ankylosing spondylitis and psoriatic arthritis. The findings indicated a significant clinical benefit for the management of these patients, despite an increased risk of adverse events in ankylosing spondylitis patients.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)

Add to Collection

Article Dermatology

Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study

Marcus Schmitt-Egenolf et al.

Summary: This retrospective observational study conducted in Sweden from 2010 to 2018 analyzed 2292 adults with psoriasis who were treated with biologics. The study revealed that despite the chronic nature of psoriasis, the persistence with biologics was relatively low. Changes in therapeutic landscape influenced the persistence over time, providing patients with more options to switch biologic treatments.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Biology

Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis

Flavia Anghel et al.

Summary: Psoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents have led to improved clinical efficacy, but further research is needed to monitor potential changes in metabolic parameters induced by treatment. Obesity, a comorbidity associated with psoriasis, may be both a risk factor and a result of the disease, as well as an adverse effect of long-term therapy with certain biologics. The increase in body mass index (BMI) due to drug treatment appears to contribute to disease progression, drug discontinuation, and reduced clinical efficacy of monoclonal antibodies.

LIFE-BASEL (2021)

Add to Collection

Article Dermatology

Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan

Megumi Kishimoto et al.

JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

Richard B. Warren et al.

DERMATOLOGY AND THERAPY (2020)

Add to Collection

Article Dermatology

Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis

April W. Armstrong et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Review Multidisciplinary Sciences

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

Johan Burisch et al.

PLOS ONE (2020)

Add to Collection

Article Dermatology

Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors

Shari Wright et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Dermatology

Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis

Yayoi Tada et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups

Ros Wade et al.

SYSTEMATIC REVIEWS (2020)

Add to Collection

Review Immunology

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments

Paolo Gisondi et al.

VACCINES (2020)

Add to Collection

Review Rheumatology

Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis

Yufeng Yin et al.

ARTHRITIS RESEARCH & THERAPY (2020)

Add to Collection

Article Dermatology

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

Alexander Egeberg et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Review Dermatology

Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis

A. Mourad et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

Add to Collection

Review Dermatology

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis

Jawad Bilal et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2018)

Add to Collection

Article Dermatology

Differential Drug Survival of Second-line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Ireny Y. K. Iskandar et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)

Add to Collection

Article Rheumatology

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort

Monika Hebeisen et al.

JOURNAL OF RHEUMATOLOGY (2018)

Add to Collection

Review Multidisciplinary Sciences

Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

Siddharth Singh et al.

PLOS ONE (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon et al.

LANCET (2018)

Add to Collection

Article Dermatology

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial

Kristian Reich et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Kristian Reich et al.

LANCET (2017)

Add to Collection

Review Dermatology

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management

D. M. Saunte et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

Add to Collection

Article Rheumatology

The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries

Pil Hojgaard et al.

RHEUMATOLOGY (2016)

Add to Collection

Review Dermatology

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

Anthony A. Gaspari et al.

DERMATOLOGIC THERAPY (2015)

Add to Collection

Article Medicine, General & Internal

Psoriasis

Wolf-Henning Boehncke et al.

LANCET (2015)

Add to Collection

Review Medicine, Research & Experimental

Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders

Jacqueline M. Benson et al.

MABS (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.